Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal

Olena Oliveira, Rita Gaio, Miguel Villar, Raquel Duarte
European Respiratory Journal 2013 42: 1747-1749; DOI: 10.1183/09031936.00197912
Olena Oliveira
1Dept of Clinical Epidemiology, Predictive medicine and Public Health of the University of Porto Medical School, Porto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: radomoliveira@gmail.com
Rita Gaio
2Dept of Mathematics, Sciences Faculty, Porto University, Porto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel Villar
3National Centre for Multidrug-resistant tuberculosis of Portugal, Lisbon
4Chest Disease Centre of Venda Nova, Amadora
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raquel Duarte
1Dept of Clinical Epidemiology, Predictive medicine and Public Health of the University of Porto Medical School, Porto
5Dept of Pulmonology, Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Vila Nova de Gaia
6Reference Centre for Multidrug-resistant tuberculosis in the North Region of Portugal, Chest Disease Centre of Vila Nova de Gaia, Vila Nova de Gaia
7Institute of Public Health University of Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Despite progress in tuberculosis (TB) control, the response to the multidrug- resistant (MDR) TB and extensively drug-resistant (XDR) TB epidemic continues to be limited. The proportion of MDR-TB patients who successfully completed treatment varied from 44% (Eastern Mediterranean Region) to 58% (South-East Asia Region) [1]. Overall, treatment success was 48%, while 28% of cases were reported as lost to follow-up or had no outcome information [1]. The Global Plan's target for 2015 of achieving at least 75% treatment success in MDR-TB patients was only reached by 30 out of 107 countries [1].

In the present paper, we evaluated the treatment outcomes of M/XDR-TB patients in Portugal. Patients with pulmonary TB resistant to isoniazid and rifampin, who started treatment at some point between January 2000 and December 2008, were selected from the national database, which integrates the data from the mandatory registration of TB cases. The evaluation of treatment outcomes was conducted from February to April 2011. Patients were classified as having received no previous treatment for TB or as having received previous treatment(s) for TB. The World Health Organization (WHO) standard definitions were used to MDR-TB, XDR-TB and treatment outcome (treatment success, died, failure, default and transferred out) [1, 2]. Was analysed the relationship between treatment outcome and clinical and demographic factors. It were also identified the predictors of poor outcome in a population of M/XDR-TB patients. The association between explanatory variables and treatment outcome was evaluated by logistic regression models. The crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were determined.

We assessed MDR-TB treatment outcomes in 364 patients (257 with MDR-TB and 107 with XDR-TB), while 11 (3%) patients had no recorded final outcome (transferred out). The median age of the patients was 40 years (range: 13–86) and 259 (71.2%) patients were male. The amount of the patients that were HIV-positive was 108 (30.5%). The proportion of cases resistant to all first-line anti-TB drugs was 19.2%. Results of drug susceptibility testing (DST) to second-line drugs (amikacin, kanamycin, capreomycin, ofloxacin, ciprofloxacin, cycloserine, ethionamide, para-aminosalycilic acid, thiacetazone) were analysed. Patients with MDR-TB had a median resistance to four drugs (with a range of 2–10) and those with XDR-TB had a median resistance to eight drugs (with a range 4–10) (p<0.001). The assessment of treatment outcomes revealed that 42 (11.5%) patients were cured, 184 (50.5%) completed treatment, 92 (25.3%) died, 21 (5.8%) experienced treatment failure, and 25 (6.9%) defaulted treatment. Thus, 226 (62.1%) patients achieved a successful outcome. The treatment success rate was significantly different for patients who were never treated for TB and for patients who received previous TB treatment (68% versus 54%; p=0.01), and between patients with MDR-TB and XDR-TB (66% versus 52%; p=0.018).

Univariate analysis indicated that treatment outcome was significantly associated with injection drug use only (OR 3.34, 95% CI 1.53–7.31; p=0.003), alcohol abuse and injection drug use (OR 10.56, 95% CI 1.21–92.25; p=0.033), HIV-positive status (OR 3.38, 95% CI 2.11–5.42; p<0.001), previous TB treatment (OR 1.76, 95% CI 1.25–2.70; p=0.010), resistance to kanamycin alone (OR 1.89, 95% CI 1.20–2.99; p=0.006), and XDR-TB (OR 1.78, 95% CI 1.13–2.82; p=0.014) (table 1).

View this table:
  • View inline
  • View popup
Table 1– Predictors of poor outcome among 364 patients with multidrug-resistant (MDR) tuberculosis (TB)

The considered multiple logistic regression model included HIV-positive status, previous TB treatment and resistance to kanamycin alone as independent variables. This model indicated that HIV-positive status (adjusted OR 3.56, 95% CI 2.20–5.77; p<0.001), previous TB treatment (adjusted OR 1.72, 95% CI 1.08–2.74; p=0.023), and resistance to kanamycin alone (adjusted OR 1.68, 95% CI 1.02–2.75; p=0.013) were significant risk factors for poor treatment outcome (table 1).

In the present study, the overall treatment success rate was 62%, which is higher than the global success rate of 48% estimated by WHO [1], and is similar to the success rates reported for other individual countries (62%) [3, 4] In the current study’s population, poor outcome was related to the high case-fatality rate (25%). The average case-fatality rates in other countries have been reported as 9% [4] and 11% [3]. The high case fatality in our study may be explained by the high prevalence of HIV-positive patients (30.5%). Mortality among patients with MDR-TB HIV-positive was 44%. The risk of poor outcome in our HIV-positive patients (31%) was 3.6 times higher than in HIV-negative patients.

We found significant differences in treatment outcomes of new MDR-TB patients and patients who had previous treatment for TB (68% versus 55%; p=0.013), and that the presence of previous TB treatment was an independent risk factor for poor outcome. In the group of previously treated patients 30% of them died during treatment and 39% of these patients were HIV- positive. It is also noteworthy that 57% of MDR-TB patients in our study had never been treated for TB. The high prevalence of new cases among MDR-TB cases could be attributed to the transmission of drug-resistant strains of Mycobacteria tuberculosis in our population. Molecular fingerprinting is an important tool to understand better the role of acquired or transmitted resistance among the relapsed patients with MDR and XDR-TB [5].

We also found a significant difference in the therapeutic success of MDR-TB patients and XDR-TB patients (66% versus 52%, p=0.018). The proportion of XDR-TB cases in our population was 29.4%, but XDR-TB was not significantly associated with a poor outcome. However, resistance to kanamycin alone was an indicator of poor prognosis. It should be noted that 109 (30%) cases in our study were resistant to kanamycin, as well as 90 (83%) kanamycin-resistant cases had XDR-TB. Migliori et al. [6] suggested that resistance to capreomycin, in particular, significantly increased the risk of death and treatment failure in M/XDR-TB cases, but that resistance to either kanamycin or amikacin alone did not significantly increase the risk of poor prognosis. In the largest cohort study ever published, no single drug was associated with treatment success in cases resistant to fluoroquinolones and in XDR-TB cases [4, 7].

Our study has several limitations due to its retrospective design. According to the Directorate-General of Health report in Portugal between 2000 and 2009 the coverage of DST to first-line drugs was of 69% [8]. Therefore, the number of MDR-TB cases within that period was probably underestimated. In our study 23% of cases had no results of DSTs to second-line drugs. In addition we only analysed a limited number of factors because we were only able to consider factors that were in the form of a notification. Despite these limitations, our study was the first nationwide study in Portugal to evaluate treatment outcomes of patients with MDR-TB, and to analyse the relationship between treatment outcome and various risk factors.

In conclusion, we found that the results of treatment for MDR-TB in Portugal are similar to the worldwide situation during our study period. We observed that being HIV-positive, having a previous TB treatment or resistance to kanamycin were independent risk factors for a poor outcome in our population.

The National Tuberculosis Program in Portugal was established in 1995, but it was only defined in 2007 as a specific strategy to control MDR-TB [9], based on the WHO Global Plan to Stop TB 2006–2015. To monitor the effectiveness of anti-M/XDR-TB interventions [10], similar evidence from other countries is necessary.

Footnotes

  • Conflict of interest: None declared.

  • Received December 6, 2012.
  • Accepted July 13, 2013.
  • ©ERS 2013

References

  1. ↵
    World Health Organization. Global Tuberculosis Report 2012. Geneva, WHO Press, 2012.
  2. ↵
    1. Falzon D,
    2. Jaramillo E,
    3. Schünemann HJ,
    4. et al
    . WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516–528.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Orenstein EW,
    2. Basu S,
    3. Shah NS,
    4. et al
    . Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153–161.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Falzon D,
    2. Gandhi N,
    3. Migliori GB,
    4. et al
    . Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2013; 42: 156–168.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Robert Giffin and Sally Robinson, Rapporteurs; Institute of Medicine. Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary. Washington, The National Academies Press, 2009; p. 40.
  6. ↵
    1. Migliori GB,
    2. Lange C,
    3. Centis R,
    4. et al
    . Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155–1159.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Migliori GB,
    2. Sotgiu G,
    3. Gandhi NR,
    4. et al
    . Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169–179.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Direcção-Geral da Saúde. CRNMR. Ponto de situação a 31 de Março de 2011 [CRNMR. Point situation March 31, 2011]. http://www.dgs.pt/ Date last accessed: June 20, 2011. Date last updated: June, 20, 2011.
  9. ↵
    1. Antunes AF
    . : Direcção- Geral da Saúde. Situação epidemiológica da tuberculose e resultados em Dezembro de 2008. Programa Nacional de Luta Contra a Tuberculose (PNT) [Epidemiological situation of tuberculosis and results in December 2008. The National Tuberculosis Program]. Lisbon, Direcção-Geral da Saúde, 2009.
  10. ↵
    1. Migliori GB,
    2. Zellweger JP,
    3. Abubakar I,
    4. et al
    . European Union standards for tuberculosis care. Eur Respir J 2012; 39: 807–819.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 6 Table of Contents
European Respiratory Journal: 42 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Olena Oliveira, Rita Gaio, Miguel Villar, Raquel Duarte
European Respiratory Journal Dec 2013, 42 (6) 1747-1749; DOI: 10.1183/09031936.00197912

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Olena Oliveira, Rita Gaio, Miguel Villar, Raquel Duarte
European Respiratory Journal Dec 2013, 42 (6) 1747-1749; DOI: 10.1183/09031936.00197912
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Drug concentration in lung tissue in MDR-TB
  • Obesity in COPD: the effect of water-based exercise
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society